Firethorn Wealth Partners LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,509 shares of the company’s stock after purchasing an additional 281 shares during the quarter. Johnson & Johnson comprises approximately 0.8% of Firethorn Wealth Partners LLC’s portfolio, making the stock its 28th biggest position. Firethorn Wealth Partners LLC’s holdings in Johnson & Johnson were worth $973,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ieq Capital LLC boosted its holdings in Johnson & Johnson by 5.1% in the third quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after purchasing an additional 6,154 shares in the last quarter. RFG Advisory LLC boosted its holdings in shares of Johnson & Johnson by 2.7% in the third quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock valued at $3,900,000 after acquiring an additional 594 shares during the period. Willis Investment Counsel boosted its holdings in shares of Johnson & Johnson by 0.4% in the fourth quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock valued at $58,097,000 after acquiring an additional 1,358 shares during the period. Wambolt & Associates LLC boosted its holdings in shares of Johnson & Johnson by 2.5% in the fourth quarter. Wambolt & Associates LLC now owns 14,528 shares of the company’s stock valued at $2,566,000 after acquiring an additional 355 shares during the period. Finally, FDx Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 0.3% in the third quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock valued at $8,237,000 after acquiring an additional 153 shares during the period. 67.94% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research firms have recently weighed in on JNJ. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 1st. Morgan Stanley increased their price target on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 19th. StockNews.com initiated coverage on Johnson & Johnson in a report on Thursday, March 16th. They set a “strong-buy” rating for the company. Piper Sandler decreased their price target on Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Finally, Credit Suisse Group increased their price target on Johnson & Johnson from $168.00 to $170.00 in a report on Friday. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $173.00.
Insider Activity
In other news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.20% of the company’s stock.
Johnson & Johnson Trading Down 0.2 %
NYSE:JNJ opened at $162.31 on Tuesday. The stock has a fifty day moving average price of $158.46 and a two-hundred day moving average price of $166.96. The stock has a market capitalization of $421.80 billion, a price-to-earnings ratio of 33.96, a PEG ratio of 2.78 and a beta of 0.53. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.77 and a current ratio of 1.07. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $183.35.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The business had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. During the same quarter last year, the business posted $2.67 earnings per share. The business’s revenue for the quarter was up 5.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be given a $1.19 dividend. The ex-dividend date is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.93%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio (DPR) is currently 99.58%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.